AbbVie today announced the availability of ELAHERE® (mirvetuximab soravtansine) in Singapore for the treatment of platinum-resistant high grade serous epithelial ovarian cancer, fallopian tube or ...
Peritoneal cancer, also called primary peritoneal cancer, is a rare type of cancer, occurring in fewer than seven out of every million people in the United States. The peritoneum is a membrane that ...
The FDA granted NXP800 orphan drug designation (ODD) for the potential treatment of patients with AT-rich interactive domain-containing protein 1a (ARID1a)-deficient ovarian, fallopian tube, and ...
SB221: A proof-of-concept study to assess the combination of SON-1010 (IL12-FHAB) and atezolizumab in patients with platinum-resistant ovarian cancer. This is an ASCO Meeting Abstract from the 2024 ...
This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...
FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive Keytruda. The U.S. Food and Drug Administration (FDA) has approved PD ...